Skip to main content
. 2019 Apr 3;13:921. doi: 10.3332/ecancer.2019.921

Table 6. Summary of effect of performance status, haemoglobin and renal function on PFS.

Patient number Median progression-free survival (months) Interquartile range (months) Significance (p values)
Performance status 0 10 7.4 3.5–17.1 No significance seen
1 39 9.1 3.7–14.3
2 11 2.2 1.2–2.9
3 1 0.2
Estimated GFR ≥34 mls/min/1.73 m2 Yes 70 8.8 3.7–15.9 0.004
No 17 3.1 2.2–8.3
Haemoglobin ≥100 g/L Yes 72 8.5 3.0–15.7 0.004
No 15 3.2 2.6–9.1